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Erratum to: Farkas H, Varga L. Human Plasma-Derived, Nanofiltered, C1-Inhibitor Concentrate (Cinryze®), 
a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting from C1-Inhibitor 
Deficiency. Biol Ther. 2012;2:002.
The authors of the above-mentioned paper noticed a few errors in the text, as reported. In 
the ‘Pharmacokinetics’ section, with regards to the C1 inhibitor, Cinryze® (ViroPharma Inc.), the 
maximum plasma concentration (Cmax) (units/mL) values should read 0.68 ± 0.08 (n = 12) versus 0.85 
± 0.12 (n = 13), and not 0.68 ± 0.08 (n = 12) versus 0.33 ± 0.20 (n = 12), as reported. The authors regret 
this error, and thank Springer Healthcare for publishing the correction.
